This week on The Rob & Jai Show, an edition of the OIS Podcast, Perry Sternberg, CEO of Sydnexis, discusses the company's efforts to bring its innovative SYD-101 product to market, which aims to slow the progression of pediatric myopia.
- Challenges in Market Access: Sternberg emphasizes the challenges of market access and reimbursement, explaining that it's not just about the product’s price but also the value proposition it offers.
- Launch Plans for 2026: The company is planning for a 2026 launch, following FDA approval, with a strong focus on ensuring a positive experience for both physicians and patients.
- Global Significance of SYD-101: He highlights the global significance of SYD-101, particularly in regions with high rates of myopia like Asia, where the need for effective solutions is critical.
- Personal Mission: Reflecting on his personal mission, Sternberg expresses his desire to make a meaningful impact on children’s vision and future health.
The hosts applaud his leadership and the potential of this product to make a lasting difference in the lives of patients affected by progressive myopia.
To learn more about SYD-101 and the exciting developments in pediatric myopia treatment, be sure to listen to the full podcast episode!
